Healthcare products firm Solventum Q3 sales beat estimates, partly driven by dental segment growth

Solventum

06/11/2025 21:48

Overview

Solventum Q3 sales rise 0.7% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reaching $1.50

Company launches Transform for the Future initiative for cost savings and growth

Outlook

Solventum expects full-year organic sales growth at high end of +2.0% to +3.0% range

Solventum increases full-year adjusted EPS outlook to $5.98 to $6.08

Solventum revises free cash flow forecast to $150 mln to $250 mln

Result Drivers

ORGANIC SALES GROWTH - Driven by positive performance in Dental Solutions and Health Information Systems segments

TARIFF IMPACT - Incremental tariffs led to lower gross margins and decreased operating income margin

TRANSFORM INITIATIVE - Launch of Transform for the Future to reshape cost structure and enhance efficiency

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 sales
Beat
$2.10 bln
$2.05 bln (10 Analysts)
Q3 Adjusted EPS
Beat
$1.50
$1.43 (11 Analysts)
Q3 EPS
$7.22
Q3 Net Income
$1.27 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Solventum Corp is $85.00, about 20.4% above its November 5 closing price of $67.69

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nPn64WdzDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)